Luke Laffin, M.D.

Stories

One-time CRISPR therapy keeps cholesterol lower for a full year in early trial

Leading the CTX310 clinical program at Cleveland Clinic

CRISPR Therapeutics' CTX310 cut triglycerides by 63% and ANGPTL3 by 65% a month after one infusion in 10 patients with severely high triglycerides, the company reported Nov. 9 at the American Heart Association meeting. The Phase 1b results follow a Phase 1a trial in which the same one-time treatment kept LDL cholesterol about 52% lower for a year.

Updated 2 days ago

Kaiser trial finds digital reminders raise statin refills modestly

New Capabilities

Published commentary arguing the trial's main value is its research model

All 20,604 patients in the trial had low statin adherence: they filled their prescriptions less than 80% of the time in the prior year and had no refill in the prior three months. Kaiser Permanente sent them a secure portal message, a text, a nonsecure email, or nothing beyond usual communication, then counted who refilled.

Updated 7 days ago

Notable Quotes

Building upon the initial data presented in November 2025, the durability of the lipid-lowering effect was impressive. It is encouraging that there were no serious safety events related to CTX310 in the trial and in the year following treatment.

from One-time CRISPR therapy keeps cholesterol lower for a full year in early trial · Updated 2 days ago

The principal contribution of ADHERE-ASCVD may not be the modest improvement in statin adherence, but the demonstration that important clinical questions can be tested rapidly and rigorously within existing health system infrastructure.

from Kaiser trial finds digital reminders raise statin refills modestly · Updated 7 days ago